What were the key takeaways from Belite Bio’s earnings call?

Did Belite Bio beat or miss consensus estimates last quarter?

What is Belite Bio's gross profit margin?

What does Belite Bio do and what are its main business segments?

What were the key takeaways from Belite Bio's earnings call?

What is the revenue and EPS growth rate for Belite Bio year over year?

What is Belite Bio's latest dividend and current dividend yield?

What guidance did Belite Bio's management provide for the next earnings period?

- **FDA NDA submission Q2 2026; 36% lesion growth reduction vs. placebo, 72-75 subjects enrolled in DRAGON II.

**【Management Opening Remarks】**
- Announced Phase III DRAGON trial success: 36% reduction in lesion growth rate vs. placebo, positioning for FDA NDA submission in Q2 2026.
- Enrolled 72-75 subjects in DRAGON II (Japan-focused) and 530 in Phase III PHOENIX trial for geographic atrophy (GA). Raised $402M in Q4 public offering, total cash of $772.6M, supporting commercialization and pipeline expansion.

**【CFO Financial Commentary】**
- Q4 2025: Net loss $25.3M (GAAP), $13.6M (non-GAAP). Full year R&D/S&A expenses: $45.4M/$38.9M (GAAP), $36.2M/$9.1M (non-GAAP). 2026 R&D budget: $150M; commercialization: $200-250M over 3 years.
- 2025 cash balance: $772.6M (vs. $145.2M in 2024), enabling U.S. launch and ex-U.S. regulatory submissions.

**【CEO & CMO/CFO Q&A Highlights】**
- U.S. launch expected Q1 2027 with 25-30 reps; Japan-focused DRAGON II trial data required for PMDA submission.
- Pricing target: $350K+ (rare disease benchmark), with 53K U.S. patients identified via genetic databases.
- GA interim look Q3 2026; pediatric trial (3-11y) planned Q2 2026, targeting 12-20y patients with 36% efficacy vs. placebo, vs. 15% GA trial interim look expected H2 2026; 15% visual acuity threshold for regulatory approval.
- Ex-U.S. submissions prioritized after FDA approval; EMA and PMDA engagement pending U.S. NDA outcome.


Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript

- **Clinical Milestones**: Completed Phase III enrollment for GA and Stargardt's disease, with DRAGON trial top-line data expected by end of November.
- **Regulatory Progress**: Secured priority review in China and conditional authorization in the UK, with global submissions planned for H1 2026.
- **Funding Strength**: $275.6 million cash post-Q3, supported by $175 million in recent financings and potential $165 million from warrant exercises.
- **Commercialization Plan**: Targeting U.S. launch with 20-40-person sales force, estimating $200 million in commercialization costs.
- **Financial Health**: Q3 net loss of $21.7 million driven by non-cash expenses, with stable operating cash outflow of $9.3 million.

**【CEO Summary Section】**
- Completed Phase III enrollment for GA (530 subjects) and Stargardt's disease (DRAGON trial). Final top-line data for DRAGON expected by end of November 2025.
- Received regulatory approvals for priority review in China (NMPA) and conditional marketing authorization in the UK (MHRA) based on interim DRAGON trial results.
- Secured $50 million registered direct offering and $125 million private placement, with potential additional $165 million from warrant exercises, providing $275.6 million in cash as of Q3 2025.
- Planning global submissions for Tinlarebant in first half of 2026, prioritizing U.S., Japan, and other key markets.

**【CFO Financial Commentary】**
- Q3 2025 net loss of $21.7 million (vs. $8.7 million YoY), driven by $12.9 million non-cash share-based compensation expenses.
- R&D expenses: $10.3 million (vs. $6.8 million YoY) due to DRAGON and PHOENIX trials.
- G&A expenses: $12.7 million (vs. $2.9 million YoY), primarily from equity incentive plan grants.
- Operating cash outflow: $9.3 million (similar to Q2 2025).
- Total cash: $275.6 million post-Q3, sufficient for clinical trials and commercialization.

**【Q&A Highlights】**
- **Regulatory Submissions**: Plan to submit applications in China, UK, and Japan in first half of 2026, using consistent DRAGON trial data package.
- **Share Outstanding**: Approximately 35 million shares (exact figure pending S-3 filing).
- **Japan Strategy**: Engaging PMDA for JNDA submission, targeting early market authorization.
- **PHOENIX Trial**: Interim analysis (H2 2026) will include sample size reestimation similar to DRAGON trial.
- **Commercialization Costs**: Estimate $200 million needed for U.S. launch, with initial sales force of 20-40 representatives.
- **Cash Sufficiency**: Current $275.6 million cash position, plus potential $165 million from warrants, deemed sufficient for commercial prep.


Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

- **Regulatory Momentum**: FDA recommends single-study approval for Stargardt trial if p < 0.01, with final data Q4 2025.
- **Funding Strength**: $15M raise extends cash runway to 4 years, supporting all Phase III trials.
- **Trial Progress**: All three Phase III trials (DRAGON, DRAGON II, PHOENIX) on track, with enrollment and interim analyses progressing.
- **Commercial Readiness**: CMC discussions ongoing; safety data for NDA submission expected early 2026.


**【CEO Summary Section】**
- Tinlarebant Phase III trials for Stargardt disease (DRAGON and DRAGON II) and geographic atrophy (PHOENIX) are on track:
  - DRAGON trial interim analysis (IA) met criteria, with FDA recommending completion of 24-month study for potential single-study approval.
  - DRAGON II trial has enrolled 17/60 subjects, including 10 Japanese, to support Japan NDA submission.
  - PHOENIX trial completed enrollment of 529 subjects, with interim analysis planned at the halfway mark.
- Secured $15 million in August 2025 registered direct offering, extending cash runway to 4 years.
- Breakthrough Therapy, Fast Track, and Orphan Drug designations highlight regulatory momentum.

**【CFO Financial Commentary】**
- Q2 2025 financials:
  - R&D expenses: $11 million (vs. $9.1 million YoY), driven by PHOENIX manufacturing and DRAGON II costs.
  - G&A expenses: $6.5 million (vs. $1.4 million YoY), primarily due to share-based compensation.
  - Net loss: $16.2 million (vs. $9.5 million YoY), with $8.6 million cash burn (excluding $7.6 million non-cash share-based comp).
  - Cash position: $149.2 million, supporting 4 years of operations without commercialization costs.

**【Q&A Key Highlights】**
- **FDA Pathway Clarification**: FDA recommends single-study approval if DRAGON trial achieves p < 0.01 statistical significance, avoiding need for confirmatory trial.
- **Commercialization Readiness**: CMC (chemistry, manufacturing, controls) discussions ongoing; safety data from 300+ subjects (12+ months on drug) expected by Q1 2026.
- **Trial Timelines**: 
  - DRAGON final data submission Q4 2025, potential NDA filing early 2026.
  - DRAGON II enrollment completion by end-2025.
  - PHOENIX interim analysis timing TBD, but safety data collection ongoing.
- **Sustainability**: Cash burn of $40-45 million/year for 2025-2026, with reduced spending post-milestone achievement.


Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

- **Clinical Milestone**: DRAGON trial interim analysis clears path for regulatory submission, with <10% dropout rate and stable visual acuity.
- **GA Leadership**: PHOENIX trial on track for 500-subject enrollment, outperforming injectable competitors with 20% dropout rate.
- **Cash Strength**: $157M cash balance supports 4+ years of operations, despite Q1 expenses rising 83% YoY.
- **Efficacy Signal**: Study powered for 35% treatment effect; DSMB interim review suggests potential for statistical significance.

**【CEO Clinical Update】**
- **Stargardt Disease Progression**: Phase 3 DRAGON trial interim analysis shows no need for sample size increase, with 104 subjects completing 1-year assessment. DSMB recommends submitting data for regulatory review.
- **Geographic Atrophy (GA) Expansion**: PHOENIX trial enrolling 500 global subjects, with 464 enrolled as of Q1. Japan-focused DRAGON 2 trial targets 60 subjects (10 in Japan).
- **Safety Profile**: <10% overall dropout rate in DRAGON, 3.8% due to ocular AEs (mild, transient xanthopsia/dark adaptation delay).

**【CSO Scientific Insights】**
- **DRAGON Trial Design**: 5mg daily dose reduces retinol-binding protein 4 by 80%, with identical endpoints (FAF lesion growth) across trials.
- **Visual Acuity Stabilization**: Mean change <3 letters on ETDRS scale over 24 months, with no significant loss in BCVA.
- **Efficacy Signal**: Study powered for 35% treatment effect; DSMB interim review suggests potential for statistical significance at completion.

**【CFO Financial Overview】**
- **Q1 2025 Expenses**: R&D ($9.4M vs. $6.8M YoY) and G&A ($6.1M vs. $1.6M YoY) driven by share-based compensation and clinical trial costs.
- **Cash Position**: $157.4M as of Q1, with 4+ years of runway. $15M raised via registered direct offering in Feb 2025.
- **Non-Cash Impact**: $6.7M of Q1 expenses non-cash, limiting operating cash outflow to $8.3M.

**【Q&A Key Takeaways】**
- **PHOENIX Dropout Rate**: 20% (vs. 30%+ in comparator trials), driven by oral administration and mild AE profile.
- **Regulatory Strategy**: Scheduling FDA meetings to finalize Stargardt development plan; no immediate impact from Trump drug pricing policy.
- **Financial Outlook**: Operating expenses to rise in 2025/2026 due to trial milestones, with R&D/G&A expected to moderate post-approval.

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

- **Stargardt trial success signal**: DSMB recommends regulatory review of interim data, with 9.6% dropout rate and stable visual acuity.
- **GA trial expansion**: Sample size increased to 500 to enhance success probability, targeting Q3 2025 completion.
- **Financial strength**: $145M cash runway supports Phase 3 trials without additional GA studies.
- **Regulatory path clarity**: Agencies likely to follow DSMB recommendation, with potential label expansion to adults via PK studies.

**【CEO Summary Section】**
- Tinlarebant Phase 3 trials for Stargardt disease and GA are progressing rapidly, with the DSMB recommending regulatory review of interim data from the Stargardt trial.
- GA trial enrollment increased to 500 subjects to enhance success probability, while Stargardt trials (DRAGON and DRAGON 2) are on track for 2025 completion.
- Company has a $145.2M cash runway (including $15M February 2025 raise) to support Phase 3 trials without additional GA studies.

**【CSO & CMO Clinical Updates】**
- Stargardt Phase 3 DRAGON trial interim analysis showed stable visual acuity (-3 letters) and 9.6% dropout rate, with DSMB recommending regulatory submission.
- GA PHOENIX trial has enrolled 400/500 subjects, targeting Q3 2025 completion. Dropout rate is 20%, lower than historical 30%+ in complement-based trials.
- Tinlarebant safety profile: mild, transient ocular AEs (xanthopsia, delayed dark adaptation) with no systemic risks.

**【CFO Financial Highlights】**
- 2024 R&D expenses: $29.9M (vs $28.8M in 2023), driven by Phase 2 royalties and share-based compensation.
- G&A expenses: $10.1M (vs $6.8M in 2023), due to increased share-based compensation.
- Net loss: $36.1M (vs $31.6M in 2023), with operating cash outflow of $29.2M (stable vs 2023).
- Cash & investments: $145.2M as of Q4 2024, providing full-year runway without additional GA trial costs.

**【Q&A Key Takeaways】**
- Regulatory agencies likely to align with DSMB's positive interim data recommendation for Stargardt approval.
- GA trial sample size increase aims to boost statistical power, with interim analysis expected to inform second trial timing.
- Stargardt label expansion to adults feasible via PK bridging studies, despite current trial focus on adolescents (12-20yo).

Actual		-0.33	-0.26	-0.4	-0.25	-0.27	-0.31	-0.28	-0.32	-0.45	-0.5	-0.65	-0.38
Forecast		-0.2	-0.2975	-0.32	-0.3	-0.285	-0.256	-0.288	-0.308	-0.352	-0.41	-0.4875	-0.5463
Surprise	0.00%	-65.00%	+12.61%	-25.00%	+16.67%	+5.26%	-21.09%	+2.78%	-3.90%	-27.84%	-21.95%	-33.33%	+30.44%

Actual	--	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BLTE

BLTE fundamentals

BLTE Q4 2025 Earnings

Earnings Call

You can ask Aime

BLTE

BLTE fundamentals

BLTE Q4 2025 Earnings

Earnings Call

BLTE Earnings Call Summary for Q4/20254:30 PM on Mar 2, 2026

BLTE Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

BLTE Earnings Call Summary for Q2/20254:30 PM on Aug 11, 2025

BLTE Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

BLTE Earnings Call Summary for Q4/20244:30 PM on Mar 17, 2025

You can ask Aime